Drugs / REGN4659
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03580694 | Jun 2018 → Dec 2019 | non-small cell lung carcinoma | Regeneron Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN4659 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03580694 ↗ |
| Modality | Monoclonal antibody | “REGN4659 (Anti-CTLA-4 mAb)” NCT03580694 ↗ |